CS184291A3 - Radioactive pharmaceuticals, process of their preparation and application - Google Patents

Radioactive pharmaceuticals, process of their preparation and application Download PDF

Info

Publication number: CS184291A3
Authority: CS; Czechoslovakia
Prior art keywords: acid; ligand; complex; composition according; radiopharmaceutical composition
Prior art date: 1990-06-18

Application number

CS911842A

Other languages

Czech (cs)

English (en)

Inventor

Jaime Simon

Joseph R Garlich

Keith R Frank

Kenneth Mcmillan

Original Assignee

Dow Chemical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-18

Filing date

1991-06-14

Publication date

1992-02-19

1991-06-14 Application filed by Dow Chemical Co filed Critical Dow Chemical Co

1992-02-19 Publication of CS184291A3 publication Critical patent/CS184291A3/cs

Links

238000000034 method Methods 0.000 title claims description 62
230000002285 radioactive effect Effects 0.000 title claims description 18
238000002360 preparation method Methods 0.000 title claims description 8
239000003814 drug Substances 0.000 title description 3
239000000203 mixture Substances 0.000 claims abstract description 95
239000003446 ligand Substances 0.000 claims abstract description 75
239000012217 radiopharmaceutical Substances 0.000 claims abstract description 66
229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 66
230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 66
229940120146 EDTMP Drugs 0.000 claims abstract description 60
229910052751 metal Inorganic materials 0.000 claims abstract description 38
239000002184 metal Substances 0.000 claims abstract description 38
238000002347 injection Methods 0.000 claims abstract description 27
239000007924 injection Substances 0.000 claims abstract description 27
150000003839 salts Chemical class 0.000 claims abstract description 23
229910052791 calcium Inorganic materials 0.000 claims abstract description 15
239000000243 solution Substances 0.000 claims description 80
NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 claims description 44
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
239000002253 acid Substances 0.000 claims description 22
238000007710 freezing Methods 0.000 claims description 14
230000008014 freezing Effects 0.000 claims description 14
241001465754 Metazoa Species 0.000 claims description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
229940090960 diethylenetriamine pentamethylene phosphonic acid Drugs 0.000 claims description 8
DUYCTCQXNHFCSJ-UHFFFAOYSA-N dtpmp Chemical compound OP(=O)(O)CN(CP(O)(O)=O)CCN(CP(O)(=O)O)CCN(CP(O)(O)=O)CP(O)(O)=O DUYCTCQXNHFCSJ-UHFFFAOYSA-N 0.000 claims description 8
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
235000011089 carbon dioxide Nutrition 0.000 claims description 6
KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical group [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims description 6
238000010257 thawing Methods 0.000 claims description 6
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 4
239000007983 Tris buffer Substances 0.000 claims description 4
239000003929 acidic solution Substances 0.000 claims description 4
IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 claims description 4
RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 claims description 4
KJZYNXUDTRRSPN-OUBTZVSYSA-N holmium-166 Chemical compound [166Ho] KJZYNXUDTRRSPN-OUBTZVSYSA-N 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
LHIJANUOQQMGNT-UHFFFAOYSA-N aminoethylethanolamine Chemical compound NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 claims description 3
UIWYJDYFSGRHKR-NJFSPNSNSA-N gadolinium-159 Chemical compound [159Gd] UIWYJDYFSGRHKR-NJFSPNSNSA-N 0.000 claims description 3
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
150000002500 ions Chemical class 0.000 claims 4
229910001420 alkaline earth metal ion Inorganic materials 0.000 claims 3
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
229910052790 beryllium Inorganic materials 0.000 claims 1
150000001805 chlorine compounds Chemical class 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims 1
229910052749 magnesium Inorganic materials 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229910052712 strontium Inorganic materials 0.000 claims 1
239000011575 calcium Substances 0.000 abstract description 28
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 14
238000009472 formulation Methods 0.000 abstract description 11
229910021645 metal ion Inorganic materials 0.000 abstract description 11
238000003608 radiolysis reaction Methods 0.000 abstract description 8
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
239000000523 sample Substances 0.000 description 32
230000000694 effects Effects 0.000 description 19
210000001519 tissue Anatomy 0.000 description 19
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
241000700159 Rattus Species 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
241000282472 Canis lupus familiaris Species 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
230000037396 body weight Effects 0.000 description 11
210000003205 muscle Anatomy 0.000 description 10
JSTADIGKFYFAIY-GJNDDOAHSA-K [2-[bis[[hydroxy(oxido)phosphoryl]methyl]amino]ethyl-(phosphonomethyl)amino]methyl-hydroxyphosphinate;samarium-153(3+) Chemical compound [H+].[H+].[H+].[H+].[H+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-K 0.000 description 9
230000015556 catabolic process Effects 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
238000010253 intravenous injection Methods 0.000 description 8
238000012453 sprague-dawley rat model Methods 0.000 description 8
210000002966 serum Anatomy 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
235000019445 benzyl alcohol Nutrition 0.000 description 5
239000001110 calcium chloride Substances 0.000 description 5
229910001628 calcium chloride Inorganic materials 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
239000011734 sodium Substances 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
210000000689 upper leg Anatomy 0.000 description 5
229910052772 Samarium Inorganic materials 0.000 description 4
RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 4
239000000920 calcium hydroxide Substances 0.000 description 4
229910001861 calcium hydroxide Inorganic materials 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
230000005855 radiation Effects 0.000 description 4
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
206010027452 Metastases to bone Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
238000005277 cation exchange chromatography Methods 0.000 description 3
239000013068 control sample Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
150000002739 metals Chemical class 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
FKTOIHSPIPYAPE-UHFFFAOYSA-N samarium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Sm+3].[Sm+3] FKTOIHSPIPYAPE-UHFFFAOYSA-N 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
JKTORXLUQLQJCM-UHFFFAOYSA-N 4-phosphonobutylphosphonic acid Chemical compound OP(O)(=O)CCCCP(O)(O)=O JKTORXLUQLQJCM-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010061728 Bone lesion Diseases 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
239000002449 isotope indicator Substances 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
241000143060 Americamysis bahia Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
206010006002 Bone pain Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000000655 Distemper Diseases 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
JREMHFSNYKJOBO-UHFFFAOYSA-L O.O.O[Ca]O Chemical compound O.O.O[Ca]O JREMHFSNYKJOBO-UHFFFAOYSA-L 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
208000005250 Spontaneous Fractures Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
208000014058 canine distemper Diseases 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
210000003109 clavicle Anatomy 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
229940102859 methylene diphosphonate Drugs 0.000 description 1
230000003387 muscular Effects 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
239000013110 organic ligand Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000012770 revaccination Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
VPRJMFJPKMESHB-UHFFFAOYSA-L samarium(ii) chloride Chemical compound Cl[Sm]Cl VPRJMFJPKMESHB-UHFFFAOYSA-L 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
NAWDYIZEMPQZHO-NJFSPNSNSA-N ytterbium-175 Chemical compound [175Yb] NAWDYIZEMPQZHO-NJFSPNSNSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Dispersion Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Developing Agents For Electrophotography (AREA)
Ultra Sonic Daignosis Equipment (AREA)

CS911842A 1990-06-18 1991-06-14 Radioactive pharmaceuticals, process of their preparation and application CS184291A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US53887190A	1990-06-18	1990-06-18

Publications (1)

Publication Number	Publication Date
CS184291A3 true CS184291A3 (en)	1992-02-19

Family

ID=24148781

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS911842A CS184291A3 (en)	1990-06-18	1991-06-14	Radioactive pharmaceuticals, process of their preparation and application

Country Status (32)

Country	Link
US (1)	US5762907A (is)
EP (1)	EP0462787B1 (is)
JP (2)	JP3636728B2 (is)
KR (1)	KR100219964B1 (is)
CN (1)	CN1033143C (is)
AT (1)	ATE123955T1 (is)
AU (2)	AU651112B2 (is)
BR (2)	BR9102579A (is)
CA (1)	CA2044812C (is)
CS (1)	CS184291A3 (is)
CY (1)	CY1891A (is)
DE (1)	DE69110554T2 (is)
DK (1)	DK0462787T3 (is)
EG (1)	EG19862A (is)
ES (1)	ES2073678T3 (is)
FI (1)	FI101044B (is)
GR (1)	GR3017430T3 (is)
HK (1)	HK80496A (is)
HU (1)	HU226897B1 (is)
IE (1)	IE71023B1 (is)
IL (1)	IL98536A (is)
IS (1)	IS1704B (is)
MC (1)	MC2260A1 (is)
NO (1)	NO302510B1 (is)
NZ (1)	NZ238547A (is)
PH (1)	PH30975A (is)
PL (1)	PL165699B1 (is)
PT (1)	PT97996B (is)
RU (1)	RU2095085C1 (is)
SA (1)	SA92120343B1 (is)
SK (1)	SK279598B6 (is)
ZA (1)	ZA914615B (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5410043A (en) *	1991-12-06	1995-04-25	Schering Aktiengesellschaft	Process for the production of mono-N-substituted tetraaza macrocycles
US5320829A (en) *	1991-12-10	1994-06-14	The Dow Chemical Company	Oral compositions for inhibiting plaque formation
DE4218744C2 (de) *	1992-06-04	1997-11-06	Schering Ag	Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5405601A (en) *	1993-07-02	1995-04-11	Mallinckrodt Medical Inc.	Functionalized tripodal ligands for imaging applications
CN1065769C (zh) *	1997-07-03	2001-05-16	中国原子能科学研究院	一种放射性药物制剂的制备方法
CN1092962C (zh) *	1998-01-26	2002-10-23	贾伟	一种减轻骨及骨关节疾病疼痛的药物
RU2164420C2 (ru) *	1999-02-10	2001-03-27	Государственный научный центр Российской Федерации Физико-энергетический институт им. акад. А.И. Лейпунского	Способ получения радиотерапевтического препарата
EP1191948A2 (en) *	1999-06-11	2002-04-03	Neorx Corporation	High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) *	1999-07-11	2006-08-22	Neorx Corporation	Skeletal-targeted radiation to treat bone-associated pathologies
RU2162714C1 (ru) *	2000-06-20	2001-02-10	Государственный научный центр РФ - Институт биофизики	Радиофармацевтическая композиция
AU2002249935A1 (en) *	2001-01-08	2002-08-19	Neorx Corporation	Radioactively labelled conjugates of phosphonates
RU2205030C2 (ru) *	2001-02-13	2003-05-27	Осминин Александр Георгиевич	Средство для рентгенологического исследования
RU2191033C1 (ru) *	2001-05-24	2002-10-20	Юминов Олег Аркадьевич	Радиофармацевтический препарат "астат-211" для лечения онкологических заболеваний щитовидной железы
RU2182022C1 (ru) *	2001-05-24	2002-05-10	Российская медицинская академия последипломного образования МЗ РФ	Способ лечения онкологических заболеваний щитовидной железы
US6567492B2 (en)	2001-06-11	2003-05-20	Eastern Isotopes, Inc.	Process and apparatus for production of F-18 fluoride
US7018614B2 (en) *	2002-11-05	2006-03-28	Eastern Isotopes, Inc.	Stabilization of radiopharmaceuticals labeled with 18-F
ES2347535T3 (es)	2002-11-05	2010-11-02	Ion Beam Applications S.A.	Estabilizacion de composiciones acuosas de 2-fluoro-2-desoxi-d-glucosa marcada con el isotopo 18f con etanol.
RU2297247C2 (ru) *	2005-06-20	2007-04-20	Государственное учреждение "Институт химии твердого тела" Уральского отделения Российской академии наук	Средство для контрастирования при рентгенодиагностике (варианты)
MY176175A (en) *	2013-05-13	2020-07-24	Vision Global Holdings Ltd	Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
CA2926652C (en)	2013-10-07	2021-07-20	Isotherapeutics Group, Llc	High purity therapeutic bone agents
KR102668112B1 (ko) *	2014-12-04	2024-05-23	지이 헬쓰케어 리미티드	방사성 약제로부터의 아세트알데히드의 제거 방법
RU2593017C1 (ru) *	2015-04-23	2016-07-27	Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ)	Способ получения радиофармацевтического препарата "астат-211"
WO2016187514A1 (en) *	2015-05-21	2016-11-24	Actinium Pharmaceueuticals, Inc.	Infusion administration of conjugated monoclonal antibodies
US11369700B2 (en) *	2015-05-25	2022-06-28	IGL Pharma Inc.	DOTMP kit formulations for radioisotopes
EP3302496B1 (en)	2015-05-25	2021-01-06	IGL Pharma, Inc.	Dotmp kit formulations for radioisotopes
RU2757258C1 (ru) *	2020-09-28	2021-10-12	федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский ядерный университет "МИФИ" (НИЯУ МИФИ)	Способ получения радиофармацевтического препарата с галлием-68 для визуализации метастазов скелета методом пэт

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4018883A (en) *	1975-03-10	1977-04-19	Nichols Institute For Endocrinology	Thyroxine (T4) radioimmunoassay
CA1050425A (en) *	1975-06-26	1979-03-13	Mallinckrodt	Radioimmunoassay methods for the determination of l-triiodothyronine and thyroxine
US4301140A (en) *	1979-12-14	1981-11-17	G. D. Searle & Co.	Radiopharmaceutical method for monitoring kidneys
US4341755A (en) *	1980-07-15	1982-07-27	Immuno Nuclear Corporation	Parathyroid radioimmunoassay
US4457602A (en) *	1981-04-20	1984-07-03	Olympus Optical Company Ltd.	Multiple light emission control system utilizing electronic flashes
US4411881A (en) *	1982-07-12	1983-10-25	New England Nuclear Corporation	Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
US5059412A (en) *	1984-06-04	1991-10-22	The Dow Chemical Company	Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) *	1984-06-04	1991-11-12	The Dow Chemical Company	Macrocyclic aminophosphonic acid complexes, their formulations and use
ZA852799B (en) *	1984-06-04	1986-12-30	Dow Chemical Co	Organic amine phosphonic acid complexes for the treatment of calcific tumors
US4898724A (en) *	1984-06-04	1990-02-06	The Dow Chemical Company	Organis amine phosphonic acid complexes for the treatment of calcific tumors
GB8510726D0 (en) *	1985-04-26	1985-06-26	Amersham Int Plc	Stabilised radio-labelled compounds
US4752464A (en) *	1985-06-07	1988-06-21	Cadema Medical Products, Inc.	Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
NZ222304A (en) *	1987-05-18	1990-10-26	Dow Chemical Co	Suppression of bone marrow using samarium-153, gadolinium-159 or holmium-166 complexes
US4853209A (en) *	1987-05-18	1989-08-01	The Dow Chemical Company	Bone marrow suppressing agents
EP0367787B2 (en) *	1987-06-30	1999-01-27	Mallinckrodt, Inc. (a Delaware corporation)	Method for enhancing the safety of metal-ligand chelates as x-ray contrast agents
US4882142A (en) *	1988-12-19	1989-11-21	The Dow Chemical Company	Bone marrow suppressing agents
US4937333A (en) *	1989-08-04	1990-06-26	The Dow Chemical Company	Method for purifying aminomethylenephosphonic acids for pharmaceutical use
US5219556A (en) *	1990-07-09	1993-06-15	Mallinckrodt Medical, Inc.	Stabilized therapeutic radiopharmaceutical complexes

1991
- 1991-06-11 MC MC912192A patent/MC2260A1/fr unknown
- 1991-06-14 PH PH42625A patent/PH30975A/en unknown
- 1991-06-14 NZ NZ238547A patent/NZ238547A/en not_active IP Right Cessation
- 1991-06-14 IS IS3717A patent/IS1704B/is unknown
- 1991-06-14 SK SK1842-91A patent/SK279598B6/sk not_active IP Right Cessation
- 1991-06-14 CS CS911842A patent/CS184291A3/cs unknown
- 1991-06-14 BR BR919102579A patent/BR9102579A/pt not_active Application Discontinuation
- 1991-06-17 CN CN91104343A patent/CN1033143C/zh not_active Expired - Lifetime
- 1991-06-17 FI FI912933A patent/FI101044B/fi not_active IP Right Cessation
- 1991-06-17 IL IL9853691A patent/IL98536A/en not_active IP Right Cessation
- 1991-06-17 JP JP14473591A patent/JP3636728B2/ja not_active Expired - Fee Related
- 1991-06-17 RU SU914895658A patent/RU2095085C1/ru not_active IP Right Cessation
- 1991-06-17 HU HU9102011A patent/HU226897B1/hu unknown
- 1991-06-17 AU AU78470/91A patent/AU651112B2/en not_active Expired
- 1991-06-17 PT PT97996A patent/PT97996B/pt not_active IP Right Cessation
- 1991-06-17 KR KR1019910010012A patent/KR100219964B1/ko not_active Expired - Lifetime
- 1991-06-17 NO NO912345A patent/NO302510B1/no not_active IP Right Cessation
- 1991-06-17 CA CA002044812A patent/CA2044812C/en not_active Expired - Lifetime
- 1991-06-17 ZA ZA914615A patent/ZA914615B/xx unknown
- 1991-06-17 IE IE205791A patent/IE71023B1/en not_active IP Right Cessation
- 1991-06-18 DE DE69110554T patent/DE69110554T2/de not_active Expired - Lifetime
- 1991-06-18 PL PL91290717A patent/PL165699B1/pl not_active IP Right Cessation
- 1991-06-18 AT AT91305485T patent/ATE123955T1/de not_active IP Right Cessation
- 1991-06-18 EP EP91305485A patent/EP0462787B1/en not_active Expired - Lifetime
- 1991-06-18 DK DK91305485.4T patent/DK0462787T3/da active
- 1991-06-18 ES ES91305485T patent/ES2073678T3/es not_active Expired - Lifetime
- 1991-06-26 EG EG37491A patent/EG19862A/xx active
1992
- 1992-01-19 SA SA92120343A patent/SA92120343B1/ar unknown
1993
- 1993-10-07 US US08/133,806 patent/US5762907A/en not_active Expired - Lifetime
1994
- 1994-06-06 AU AU64559/94A patent/AU665911B2/en not_active Expired
1995
- 1995-09-18 GR GR950402555T patent/GR3017430T3/el unknown
1996
- 1996-05-09 HK HK80496A patent/HK80496A/en not_active IP Right Cessation
- 1996-08-30 CY CY189196A patent/CY1891A/xx unknown
1997
- 1997-05-14 BR BR1101169-6A patent/BR1101169A/pt active IP Right Grant
2001
- 2001-10-11 JP JP2001314293A patent/JP2002114712A/ja not_active Ceased

Also Published As

Publication number	Publication date
PH30975A (en)	1997-12-23
IE912057A1 (en)	1991-12-18
DK0462787T3 (da)	1995-10-30
GR3017430T3 (en)	1995-12-31
IL98536A0 (en)	1992-07-15
IE71023B1 (en)	1997-01-15
BR1101169A (pt)	2000-08-08
DE69110554D1 (de)	1995-07-27
AU665911B2 (en)	1996-01-18
SK279598B6 (sk)	1999-01-11
HK80496A (en)	1996-05-17
CA2044812A1 (en)	1991-12-19
AU6455994A (en)	1994-08-04
SA92120343B1 (ar)	2004-01-25
RU2095085C1 (ru)	1997-11-10
CA2044812C (en)	2002-12-31
DE69110554T2 (de)	1995-12-14
PT97996B (pt)	1998-11-30
PT97996A (pt)	1992-03-31
FI912933L (fi)	1991-12-19
HU912011D0 (en)	1991-12-30
US5762907A (en)	1998-06-09
JP3636728B2 (ja)	2005-04-06
EP0462787A1 (en)	1991-12-27
PL290717A1 (en)	1992-02-24
CY1891A (en)	1996-08-30
AU651112B2 (en)	1994-07-14
JPH04230224A (ja)	1992-08-19
BR9102579A (pt)	1992-01-21
EP0462787B1 (en)	1995-06-21
ATE123955T1 (de)	1995-07-15
MC2260A1 (fr)	1993-04-26
IS1704B (is)	1998-12-10
KR920000334A (ko)	1992-01-29
AU7847091A (en)	1991-12-19
IL98536A (en)	1996-10-31
NO302510B1 (no)	1998-03-16
KR100219964B1 (ko)	1999-09-01
NO912345D0 (no)	1991-06-17
CN1063615A (zh)	1992-08-19
FI912933A0 (fi)	1991-06-17
HU226897B1 (en)	2010-01-28
HUT57994A (en)	1992-01-28
NO912345L (no)	1991-12-19
PL165699B1 (pl)	1995-01-31
CN1033143C (zh)	1996-10-30
ES2073678T3 (es)	1995-08-16
JP2002114712A (ja)	2002-04-16
IS3717A7 (is)	1991-12-19
ZA914615B (en)	1993-02-24
FI101044B (fi)	1998-04-15
EG19862A (en)	1996-06-30
NZ238547A (en)	1994-05-26

Legal Events

Date	Code	Title	Description
2000-06-30	PD00	Pending as of 2000-06-30 in czech republic

Publication	Publication Date	Title
CS184291A3 (en)	1992-02-19	Radioactive pharmaceuticals, process of their preparation and application
KR102698269B1 (ko)	2024-09-02	납 또는 토륨 방사성핵종에 연결된 psma-타게팅 화합물을 포함하는 복합체
ES2314977T3 (es)	2009-03-16	Agentes radioterapeuticos que contienen estaño-117m.
JPH05271102A (ja)	1993-10-19	放射性薬剤の制菌剤
AU650944B2 (en)	1994-07-07	Method of treating and/or diagnosing soft tissue tumors
EP1292338B1 (en)	2012-09-19	Stabiliser for radiopharmaceuticals
AU2001264133A1 (en)	2002-03-21	Stabiliser for radiopharmaceuticals
EP1438076B1 (en)	2006-06-14	Radiopharmaceutical agent for the treatment of early stage cancer
RU2817970C1 (ru)	2024-04-23	Лиофилизат на основе лигандов к простат-специфическому мембранному антигену (ПСМА) для приготовления радиофармацевтической композиции в форме раствора для инъекций для лечения рака предстательной железы, радиофармацевтическая композиция на ее основе для лечения рака предстательной железы и способ приготовления радиофармацевтической композиции
US12268758B2 (en)	2025-04-08	DOTMP kit formulations for radioisotopes
AU654169B2 (en)	1994-10-27	Compositions and method for soft tissue tumors
WO2025042307A1 (ru)	2025-02-27	Лиофилизат, фармацевтическая композиция и способ её приготовления
Zolle et al.	2007	12.7. 2 99mTc-Diphosphonates
JPH01283229A (ja)	1989-11-14	Ｔｃ‐９９ｍ‐ω‐アルキルホスフイニコ‐１‐ヒドロキシアルカン‐１，１‐ジホスホネート含有生成物